BJE6-106 (B106) (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations. BJE6-106 (B106) (0.2 μM, 0.5 μM; 6- 24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells. BJE6-106 (B106) (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing MKK4, JNK and H2AX activation at different times in SBcl2 cells.
Cell Viability Assay
| Cell Line: | Melanoma cell lines with NRAS mutations: SBcl2, FM6, SKMEL2, WM1366, WM1361A, and WM852 cells |
| Concentration: | 0.2 μM, 0.5 μM |
| Incubation Time: | 24 hours, 48 hours, or 72 hours |
| Result: | Inhibited cell survival in melanoma cell lines. |
Apoptosis Analysis
| Cell Line: | < td class="col2"> SBcl2 cells
| Concentration: | 0.2 μM, 0.5 μM |
| Incubation Time: | 6 hours, 12 hours, or 24 hours |
| Result: | Induced caspase 3/7 activation. |
Western Blot Analysis
| Cell Line : | SBcl2 cells |
| Concentration: | 0.2 μM , 0.5 μM |
| Incubation Time: | 2 hours, 5 hours, 10 hours | < /tr>
Result: | Increased phosphorylation of MKK4, JNK and H2AX. |
